GLENMARK
Glenmark Pharmaceuticals Limited
Each stock's 10,000-path forecast, rendered as light.
Glenmark Pharmaceuticals Limited (GLENMARK) Stock Analysis & Case Study
Is GLENMARK a good buy? The data-driven verdict.
Glenmark Pharmaceuticals Limited (GLENMARK) trades at ₹2,279,on the numbers it worth a closer look, a Downstox Snapshot Score of 68/100.
On the numbers, Glenmark Pharmaceuticals Limited (GLENMARK) worth a closer look, a Downstox Snapshot Score of 68/100, weighing fairly valued at 20.6× earnings, ROE of 30.5%, a 59% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
GLENMARK fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How GLENMARK ranks against the 2,371 companies in our screener
- GLENMARK's market cap of 64,316 Cr ranks in the 93rd percentile of the 2,371 NSE companies in our screener, as of 8 Aug 2026.
- GLENMARK's book value of ₹372 ranks in the 85th percentile of the 2,371 NSE companies in our screener, as of 8 Aug 2026.
- GLENMARK's promoter holding of 46.6% ranks in the 25th percentile of the 2,371 NSE companies in our screener, as of 8 Aug 2026.
- GLENMARK's 3-year profit (PAT) growth of 76.0% ranks in the 91st percentile of the 2,371 NSE companies in our screener, as of 8 Aug 2026.
- GLENMARK's 3-year revenue growth of 14.0% ranks in the 60th percentile of the 2,371 NSE companies in our screener, as of 8 Aug 2026.
- GLENMARK's debt-to-equity ratio of 0.06x is lower than 84% of the 2,371 NSE companies in our screener, as of 8 Aug 2026.
Is GLENMARK overvalued? GLENMARK P/E vs peers
GLENMARK trades at 20.6× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
GLENMARK share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of GLENMARK history (10%/yr drift, 30%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| GLENMARK 2027 | ₹1,656 | ₹2,442 | ₹3,600 | +7% |
| GLENMARK 2028 | ₹1,495 | ₹2,616 | ₹4,577 | +15% |
| GLENMARK 2029 | ₹1,418 | ₹2,802 | ₹5,538 | +23% |
| GLENMARK 2030 | ₹1,385 | ₹3,002 | ₹6,507 | +32% |
| GLENMARK 2031 | ₹1,336 | ₹3,216 | ₹7,741 | +41% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability GLENMARK goes up, or doubles?
The bull case for GLENMARK
- GLENMARK's P/E of 20.6x is lower than 61% of the 2,371 NSE companies in our screener, as of 8 Aug 2026.
- GLENMARK's return on equity of 30.5% ranks in the 94th percentile of the 2,371 NSE companies in our screener, as of 8 Aug 2026.
- GLENMARK's return on capital employed of 39.8% ranks in the top 3% of the 2,371 NSE companies in our screener, as of 8 Aug 2026.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹5,538.
The bear case & risks
- No model or past record guarantees future returns, treat this as one input, not a decision.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹1,418.
GLENMARK volatility & expected range, how bumpy is the ride?
Over the last 9.8 years GLENMARK compounded at 10%/year with annualized volatility of 30%. That volatility implies a 1-year 80% range of ₹1,656-₹3,600, the honest backbone behind any single price target.
GLENMARK price forecast, the full 60-month probability fan
GLENMARK price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds GLENMARK hits common targets within the simulated horizon?
Full multi-horizon detail on the GLENMARK price target & forecast page.
GLENMARK Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. GLENMARK scores 6/8, mixed financial health.
GLENMARK MTF margin & leverage across 10 brokers
Margin Trading Facility lets you buy GLENMARK with part of the capital. Lower margin % = higher leverage. Rates compared across 10 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 25.73% | 3.9× |
| Zerodha | 24.90% | 4.0× |
| Groww | 24.97% | 4.0× |
| Dhan | 23.00% | 4.3× |
| Kotak NeoCHEAPEST | 22.22% | 4.5× |
| Paytm Money | 22.33% | 4.5× |
| Pocketful | 29.35% | 3.4× |
| Anand Rathi | 29.20% | 3.4× |
| Bajaj Broking | 24.00% | 4.2× |
| Share India | 29.30% | 3.4× |
Compare every broker on the GLENMARK MTF page.
About Glenmark Pharmaceuticals Limited: sector, index & market-cap context
Glenmark Pharmaceuticals Limited (GLENMARK) is a mid-cap NSE-listed company, and a constituent of the Nifty 500 index, with a market capitalisation of ₹64,316 Cr. See more stocks on our screener.
How the GLENMARK Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Glenmark Pharmaceuticals Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
GLENMARK analysis, FAQs
Is Glenmark Pharmaceuticals Limited (GLENMARK) a good buy?
On the numbers, Glenmark Pharmaceuticals Limited (GLENMARK) worth a closer look, a Downstox Snapshot Score of 68/100, weighing fairly valued at 20.6× earnings, ROE of 30.5%, a 59% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is GLENMARK overvalued or undervalued?
GLENMARK trades at 20.6× earnings, fairly valued versus the ~22× long-run Nifty average.
What is the GLENMARK share price target for 2031?
GLENMARK's probability-weighted 2031 median target is ₹3,216, with an 80% range of ₹1,336-₹7,741 (10,000-path Monte-Carlo).
What is the probability GLENMARK doubles in 5 years?
The modelled probability of GLENMARK reaching ₹4,558 (2×) within 5 years is 30%.
What is the bull case for GLENMARK?
GLENMARK's P/E of 20.6x is lower than 61% of the 2,371 NSE companies in our screener, as of 8 Aug 2026. GLENMARK's return on equity of 30.5% ranks in the 94th percentile of the 2,371 NSE companies in our screener, as of 8 Aug 2026. GLENMARK's return on capital employed of 39.8% ranks in the top 3% of the 2,371 NSE companies in our screener, as of 8 Aug 2026.
What are the risks in GLENMARK?
No model or past record guarantees future returns, treat this as one input, not a decision.